Functional characterization of BK virus-specific CD4+ T cells with cytotoxic potential in seropositive adults. 2007

Wendi Zhou, and Madeva Sharma, and Joy Martinez, and Tumul Srivastava, and Don J Diamond, and Wendy Knowles, and Simon F Lacey
Laboratory of Vaccine Research, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.

BK polyomavirus (BKV) reactivation is associated with a failure of T cell immunity in kidney transplant patients, and may lead to BKV-associated nephropathy (BKVN) and loss of the allograft. BKV reactivation in hematopoietic stem cell transplant recipients is associated with hemorrhagic cystitis. We have investigated T cell responses to overlapping peptide mixtures corresponding to the whole BKV major T antigen (TAg) and major capsid protein (VP1) in peripheral blood mononuclear cell samples from a cohort of healthy BKV-seropositive subjects. The majority of these individuals possessed populations of both CD8(+) and CD4(+) T cells specific for these BKV antigens. After expansion in culture, the majority of the BKV-specific CD4(+) T cells, in addition to expressing CD40L (CD154), secreted both interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha, contained both granzyme A and granzyme B, and degranulated/mobilized CD107 in response to antigen-specific stimulation. These T cells thus represent potentially functional BKV-specific cytotoxic CD4(+) T lymphocytes. Secretion of both TNF-alpha and IFN-gamma by CD154(+)CD4(+) T cells on BKV-specific stimulation was associated with higher levels of granzyme B and a higher proportion of degranulating cells compared with CD154(+)CD4(+) T cells producing only IFN-gamma or neither cytokine. These healthy subjects also harbored populations of functional CD8(+) T cells specific for one or more of three newly defined HLA-A 02-restricted cytotoxic T lymphocyte epitopes within the BKV TAg as well as two HLA-A 02-restricted epitopes within the BKV VP1 we have previously described. The BKV-specific CD4(+) T cells characterized in this study may play a part in maintaining persistent memory T cell responses to the virus and thus contribute to the immune control of BKV in healthy individuals.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D001739 BK Virus A species of POLYOMAVIRUS apparently infecting over 90% of children but not clearly associated with any clinical illness in childhood. The virus remains latent in the body throughout life and can be reactivated under certain circumstances. BK polyomavirus,Human Polyomavirus BK,Polyomavirus, BK,Polyomavirus hominis 1,Polyomavirus BK, Human
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D014412 Tumor Virus Infections Infections produced by oncogenic viruses. The infections caused by DNA viruses are less numerous but more diverse than those caused by the RNA oncogenic viruses. Fibroma, Shope,Papilloma, Shope,Infections, Tumor Virus,Infection, Tumor Virus,Shope Fibroma,Shope Papilloma,Tumor Virus Infection

Related Publications

Wendi Zhou, and Madeva Sharma, and Joy Martinez, and Tumul Srivastava, and Don J Diamond, and Wendy Knowles, and Simon F Lacey
December 2003, Journal of the American Society of Nephrology : JASN,
Wendi Zhou, and Madeva Sharma, and Joy Martinez, and Tumul Srivastava, and Don J Diamond, and Wendy Knowles, and Simon F Lacey
September 2013, Journal of virology,
Wendi Zhou, and Madeva Sharma, and Joy Martinez, and Tumul Srivastava, and Don J Diamond, and Wendy Knowles, and Simon F Lacey
January 2002, Journal of immunology (Baltimore, Md. : 1950),
Wendi Zhou, and Madeva Sharma, and Joy Martinez, and Tumul Srivastava, and Don J Diamond, and Wendy Knowles, and Simon F Lacey
November 2013, Journal of virology,
Wendi Zhou, and Madeva Sharma, and Joy Martinez, and Tumul Srivastava, and Don J Diamond, and Wendy Knowles, and Simon F Lacey
January 1996, Immunology,
Wendi Zhou, and Madeva Sharma, and Joy Martinez, and Tumul Srivastava, and Don J Diamond, and Wendy Knowles, and Simon F Lacey
January 1991, Clinical and experimental immunology,
Wendi Zhou, and Madeva Sharma, and Joy Martinez, and Tumul Srivastava, and Don J Diamond, and Wendy Knowles, and Simon F Lacey
April 1992, Journal of virology,
Wendi Zhou, and Madeva Sharma, and Joy Martinez, and Tumul Srivastava, and Don J Diamond, and Wendy Knowles, and Simon F Lacey
May 2010, Journal of immunology (Baltimore, Md. : 1950),
Wendi Zhou, and Madeva Sharma, and Joy Martinez, and Tumul Srivastava, and Don J Diamond, and Wendy Knowles, and Simon F Lacey
January 2019, The New England journal of medicine,
Wendi Zhou, and Madeva Sharma, and Joy Martinez, and Tumul Srivastava, and Don J Diamond, and Wendy Knowles, and Simon F Lacey
January 2019, The New England journal of medicine,
Copied contents to your clipboard!